Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mühlbacher A[au]:

Search results

Items: 1 to 50 of 98

1.

Patient Preferences Concerning Alternative Treatments for Neuroendocrine Tumors: Results of the "PIANO-Study".

Mühlbacher AC, Juhnke C.

Int J Technol Assess Health Care. 2019 Jan;35(3):243-251. doi: 10.1017/S0266462319000217. Epub 2019 May 2.

PMID:
31044688
2.

Systematic Review of Public Preferences for the Allocation of Donor Organs for Transplantation: Principles of Distributive Justice.

Oedingen C, Bartling T, Mühlbacher AC, Schrem H, Krauth C.

Patient. 2019 Oct;12(5):475-489. doi: 10.1007/s40271-019-00363-0. Review.

PMID:
30957196
3.

A multicentre evaluation of the Elecsys® HIV Duo assay.

Mühlbacher A, Sauleda S, Piron M, Rietz R, Permpikul P, Klinkicht M, Gloeck M, Imdahl R.

J Clin Virol. 2019 Mar;112:45-50. doi: 10.1016/j.jcv.2018.11.005. Epub 2018 Nov 20.

PMID:
30611626
4.

The Value of Treatment Processes in Germany: A Discrete Choice Experiment on Patient Preferences in Complementary and Conventional Medicine.

Adam D, Keller T, Mühlbacher A, Hinse M, Icke K, Teut M, Brinkhaus B, Reinhold T.

Patient. 2019 Jun;12(3):349-360. doi: 10.1007/s40271-018-0353-1.

5.

A discrete choice experiment to investigate patient preferences for HIV testing programs in Bogotá, Colombia.

Wijnen BFM, Van Engelen RPLB, Ostermann J, Muhlbacher A, Hendriks AFW, Conde R, Gonzalez JGR, Govers MJG, Evers SMAA, Hiligsmann M.

Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):195-201. doi: 10.1080/14737167.2019.1530594. Epub 2018 Oct 8.

PMID:
30280617
6.

PATIENT PRIORITIES FOR TREATMENT ATTRIBUTES IN ADJUNCTIVE DRUG THERAPY OF SEVERE HYPERCHOLESTEROLEMIA IN GERMANY: AN ANALYTIC HIERARCHY PROCESS.

Mühlbacher AC, Kaczynski A, Dippel FW, Bethge S.

Int J Technol Assess Health Care. 2018 Jan;34(3):267-275. doi: 10.1017/S0266462318000247.

PMID:
29987994
7.

Incentives for Blood Donation: A Discrete Choice Experiment to Analyze Extrinsic Motivation.

Sadler A, Shi L, Bethge S, Mühlbacher A.

Transfus Med Hemother. 2018 Apr;45(2):116-124. doi: 10.1159/000481142. Epub 2018 Jan 10.

8.

Contract Design: Risk Management and Evaluation.

Mühlbacher AC, Amelung VE, Juhnke C.

Int J Integr Care. 2018 Jan 12;18(1):3. doi: 10.5334/ijic.3616.

9.

Contract Design: Financial Options and Risk.

Mühlbacher AC, Amelung VE, Juhnke C.

Int J Integr Care. 2018 Jan 12;18(1):2. doi: 10.5334/ijic.3615.

10.

Contract Design: The problem of information asymmetry.

Mühlbacher AC, Amelung VE, Juhnke C.

Int J Integr Care. 2018 Jan 12;18(1):1. doi: 10.5334/ijic.3614.

11.

Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: Correlation with graft survival.

Arnold ML, Bach C, Heinemann FM, Horn PA, Ziemann M, Lachmann N, Mühlbacher A, Dick A, Ender A, Thammanichanond D, Schaub S, Hönger G, Fischer GF, Mytilineos J, Hallensleben M, Hitzler WE, Seidl C, Spriewald BM.

Int J Immunogenet. 2018 Jun;45(3):95-101. doi: 10.1111/iji.12363. Epub 2018 Mar 25.

PMID:
29575597
12.

A best-worst scaling in Colombian patients to rank the characteristics of HIV/AIDS treatment.

Hendriks A, Wijnen B, van Engelen R, Conde R, Evers SM, Gonzalez J, Govers M, Mühlbacher A, Hiligsmann M.

J Med Econ. 2018 May;21(5):468-473. doi: 10.1080/13696998.2018.1440401. Epub 2018 Feb 26.

PMID:
29429371
13.

Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia.

Mühlbacher AC, Sadler A, Dippel FW, Juhnke C.

Pharmacoeconomics. 2018 Apr;36(4):477-493. doi: 10.1007/s40273-018-0614-9.

PMID:
29388056
14.

[Benefit Assessment for Examination and Treatment Methods with Medical Devices of High Hisk: Trade-off between Patient Benefit, Evidence and Access].

Mühlbacher AC, Juhnke C.

Gesundheitswesen. 2018 Mar;80(S 02):S80-S87. doi: 10.1055/s-0043-112742. Epub 2017 Jul 28. German.

PMID:
28753706
15.

Benefits and limitations of belatacept in 4 hand-transplanted patients.

Grahammer J, Weissenbacher A, Zelger BG, Zelger B, Boesmueller C, Ninkovic M, Mühlbacher A, Peschel I, Brandacher G, Öfner D, Schneeberger S.

Am J Transplant. 2017 Dec;17(12):3228-3235. doi: 10.1111/ajt.14440. Epub 2017 Sep 13.

16.

[The Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in Hepatitis C].

Mühlbacher AC, Sadler A.

Gesundheitswesen. 2019 Jan;81(1):e21-e32. doi: 10.1055/s-0043-107235. Epub 2017 Jun 19. German.

PMID:
28628931
17.

Health Preference Research: An Overview.

Craig BM, Lancsar E, Mühlbacher AC, Brown DS, Ostermann J.

Patient. 2017 Aug;10(4):507-510. doi: 10.1007/s40271-017-0253-9. No abstract available.

PMID:
28597377
18.

Preferences for Health Interventions: Improving Uptake, Adherence, and Efficiency.

Ostermann J, Brown DS, de Bekker-Grob EW, Mühlbacher AC, Reed SD.

Patient. 2017 Aug;10(4):511-514. doi: 10.1007/s40271-017-0251-y. No abstract available.

19.

Giving Patients a Meaningful Voice in European Health Technology Assessments: The Role of Health Preference Research.

Mühlbacher AC, Johnson FR.

Patient. 2017 Aug;10(4):527-530. doi: 10.1007/s40271-017-0249-5. No abstract available.

PMID:
28597373
20.

Evaluation of Sensitivity and Specificity Performance of Elecsys HTLV-I/II Assay in a Multicenter Study in Europe and Japan.

Laperche S, Sauleda S, Piron M, Mühlbacher A, Schennach H, Schottstedt V, Queirós L, Uno N, Yanagihara K, Imdahl R, Hey A, Klinkicht M, Melchior W, Muench P, Watanabe T.

J Clin Microbiol. 2017 Jul;55(7):2180-2187. doi: 10.1128/JCM.00169-17. Epub 2017 May 3.

21.

A Review on Methods of Risk Adjustment and their Use in Integrated Healthcare Systems.

Juhnke C, Bethge S, Mühlbacher AC.

Int J Integr Care. 2016 Oct 26;16(4):4. doi: 10.5334/ijic.2500.

22.

The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.

Mühlbacher AC, Sadler A.

Value Health. 2017 Feb;20(2):266-272. doi: 10.1016/j.jval.2016.12.015. Epub 2017 Feb 16.

23.

Genotyping of coeliac-specific human leucocyte antigen in children with type 1 diabetes: does this screening method make sense?

Binder E, Loinger M, Mühlbacher A, Edlinger M, Steichen E, Meraner D, Loacker L, Weigel G, Müller T, Fröhlich-Reiterer E, Hofer SE.

Arch Dis Child. 2017 Jul;102(7):603-606. doi: 10.1136/archdischild-2016-311610. Epub 2016 Dec 30.

PMID:
28039141
24.

Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment.

Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS.

J Patient Rep Outcomes. 2017;2(1):13. doi: 10.1186/s41687-018-0032-y. Epub 2018 Mar 1.

25.

What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.

Mühlbacher A, Bethge S.

Eur J Health Econ. 2016 Dec;17(9):1125-1140. Epub 2015 Dec 18.

PMID:
26682548
26.

[Patients' Priorities in the Treatment of Neuroendocrine Tumours: An Analytical Hierarchy Process].

Mühlbacher AC, Juhnke C, Kaczynski A.

Gesundheitswesen. 2016 Oct;78(10):651-657. Epub 2015 Jun 25. German.

PMID:
26110243
27.

TREATMENT AFTER ACUTE CORONARY SYNDROME: ANALYSIS OF PATIENT'S PRIORITIES WITH ANALYTIC HIERARCHY PROCESS.

Mühlbacher AC, Bethge S, Kaczynski A.

Int J Technol Assess Health Care. 2016 Jan;32(4):284-291. Epub 2016 Oct 18.

PMID:
27751189
28.

First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment.

Mühlbacher A, Bethge S.

Value Health. 2016 Sep - Oct;19(6):776-787. doi: 10.1016/j.jval.2016.04.007.

29.

Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions: The European Union Perspective.

Mühlbacher AC, Juhnke C, Beyer AR, Garner S.

Value Health. 2016 Sep - Oct;19(6):734-740. doi: 10.1016/j.jval.2016.04.006. Epub 2016 Sep 9.

30.

Evaluating the Impact of an Accountable Care Organization on Population Health: The Quasi-Experimental Design of the German Gesundes Kinzigtal.

Pimperl A, Schulte T, Mühlbacher A, Rosenmöller M, Busse R, Groene O, Rodriguez HP, Hildebrandt H.

Popul Health Manag. 2017 Jun;20(3):239-248. doi: 10.1089/pop.2016.0036. Epub 2016 Aug 26.

31.

A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.

Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Gleißner E, Mühlbacher A, Kieseier B.

Ther Adv Neurol Disord. 2016 Mar;9(2):95-104. doi: 10.1177/1756285615622736. Epub 2016 Jan 8.

32.

Choice Experiments to Quantify Preferences for Health and Healthcare: State of the Practice.

Mühlbacher A, Johnson FR.

Appl Health Econ Health Policy. 2016 Jun;14(3):253-66. doi: 10.1007/s40258-016-0232-7.

PMID:
26992386
33.

[Involving patients, the insured and the general public in healthcare decision making].

Mühlbacher AC, Juhnke C.

Z Evid Fortbild Qual Gesundhwes. 2016;110-111:36-44. doi: 10.1016/j.zefq.2015.12.001. Epub 2016 Jan 6. German.

PMID:
26875034
34.

Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Mühlbacher AC, Bridges JF, Bethge S, Dintsios CM, Schwalm A, Gerber-Grote A, Nübling M.

Eur J Health Econ. 2017 Mar;18(2):155-165. doi: 10.1007/s10198-016-0763-8. Epub 2016 Feb 4.

PMID:
26846922
35.

Experimental measurement of preferences in health care using best-worst scaling (BWS): theoretical and statistical issues.

Mühlbacher AC, Zweifel P, Kaczynski A, Johnson FR.

Health Econ Rev. 2016 Dec;6(1):5. doi: 10.1186/s13561-015-0077-z. Epub 2016 Jan 29.

36.

Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer's Disease.

Mühlbacher A, Johnson FR, Yang JC, Happich M, Belger M.

Value Health. 2016 Jan;19(1):66-74. doi: 10.1016/j.jval.2015.10.011. Epub 2016 Jan 12.

37.

Experimental measurement of preferences in health and healthcare using best-worst scaling: an overview.

Mühlbacher AC, Kaczynski A, Zweifel P, Johnson FR.

Health Econ Rev. 2016 Dec;6(1):2. doi: 10.1186/s13561-015-0079-x. Epub 2016 Jan 8.

38.

Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA.

Mühlbacher AC, Kaczynski A.

Appl Health Econ Health Policy. 2016 Feb;14(1):29-40. doi: 10.1007/s40258-015-0203-4.

PMID:
26519081
39.

Would you test for 5000 Shillings? HIV risk and willingness to accept HIV testing in Tanzania.

Ostermann J, Brown DS, Mühlbacher A, Njau B, Thielman N.

Health Econ Rev. 2015 Dec;5(1):60. doi: 10.1186/s13561-015-0060-8. Epub 2015 Aug 19.

40.

Patient Preferences for Features of Health Care Delivery Systems: A Discrete Choice Experiment.

Mühlbacher AC, Bethge S, Reed SD, Schulman KA.

Health Serv Res. 2016 Apr;51(2):704-27. doi: 10.1111/1475-6773.12345. Epub 2015 Aug 10.

41.

Reply to "Better method for evaluating a new laboratory test for syphilis".

Enders M, Gleich M, Mühlbacher A, Sakuldamrongpanich T, Turhan A, Sertöz R, Semprini S, Sambri V.

Clin Vaccine Immunol. 2015 May;22(5):607-8. doi: 10.1128/CVI.00109-15. No abstract available.

42.

Head-to-head comparison between two screening systems for HBsAG, anti-HBc, anti-HCV and HIV combination immunoassays in an international, multicentre evaluation study.

Schmidt M, Jimenez A, Mühlbacher A, Oota S, Blanco L, Sakuldamrongpanich T, Schennach H, Seifried E.

Vox Sang. 2015 Aug;109(2):114-21. doi: 10.1111/vox.12259. Epub 2015 Apr 20. Erratum in: Vox Sang. 2016 Oct;111(3):320.

PMID:
25899479
43.

Patient-centric HTA: different strokes for different folks.

Mühlbacher AC.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):591-7. doi: 10.1586/14737167.2015.1038245. Epub 2015 Apr 20.

PMID:
25896756
44.

[Objective Criteria in the Medicinal Therapy for Type II Diabetes: An Analysis of the Patients' Perspective with Analytic Hierarchy Process and Best-Worst Scaling].

Mühlbacher AC, Bethge S, Kaczynski A, Juhnke C.

Gesundheitswesen. 2016 May;78(5):326-36. doi: 10.1055/s-0034-1390474. Epub 2015 Apr 8. German.

PMID:
25853782
45.

[Patients' preferences in the medicamentous treatment of diabetes mellitus type 2: A systematic classification and meta-comparison of patient preference studies].

Mühlbacher AC, Kaczynski A.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Apr;58(4-5):452-66. doi: 10.1007/s00103-015-2127-4. Review. German.

PMID:
25687713
46.

One size does not fit all: HIV testing preferences differ among high-risk groups in Northern Tanzania.

Ostermann J, Njau B, Mtuy T, Brown DS, Mühlbacher A, Thielman N.

AIDS Care. 2015;27(5):595-603. doi: 10.1080/09540121.2014.998612. Epub 2015 Jan 23.

47.

Patient preferences for characteristics of antiretroviral therapies: results from five European countries.

Gazzard B, Ali S, Muhlbacher A, Ghafouri N, Maggiolo F, Golics C, Nozza S, Fuster MJ, Antela A, Parienti JJ, Dang N, Bregigeon SR, Benzie A, Murray M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19540. doi: 10.7448/IAS.17.4.19540. eCollection 2014.

48.

Patients' Preferences in Late Stage Treatment of Non-Small-Cell Lung Cancer: A Discrete-Choice Experiment.

Mühlbacher AC, Bethge S.

Value Health. 2014 Nov;17(7):A650. doi: 10.1016/j.jval.2014.08.2362. Epub 2014 Oct 26. No abstract available.

49.

Patients' Priorities in the Treatment of Neuroendocrine Tumors: An Analytic Hierarchy Process.

Mühlbacher AC, Juhnke C, Kaczynski A.

Value Health. 2014 Nov;17(7):A650. doi: 10.1016/j.jval.2014.08.2360. Epub 2014 Oct 26. No abstract available.

50.

Patient, Insuree and Public Participation in Health Technology Assessment: An International Comparison.

Mühlbacher AC, Juhnke C.

Value Health. 2014 Nov;17(7):A405. doi: 10.1016/j.jval.2014.08.939. Epub 2014 Oct 26. No abstract available.

Supplemental Content

Loading ...
Support Center